NCT05873205View on ClinicalTrials.gov

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

June 29, 2026

Study Completion Date

June 29, 2026

Conditions
Blood CancerRefractory Immune Cytopenias
Interventions
BIOLOGICAL

Isatuximab

All participants enrolled on the study will receive isatuximab intravenously as a single agent

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER